Programmed death receptor (PD-) 1/PD-ligand (L) 1 in urological cancers: the “all-around warrior” in immunotherapy
Q Liu, Y Guan, S Li - Molecular cancer, 2024 - Springer
Abstract Programmed death receptor-1 (PD-1) and its ligand, programmed death ligand-1
(PD-L1) are essential molecules that are key in modulating immune responses. PD-L1 is …
(PD-L1) are essential molecules that are key in modulating immune responses. PD-L1 is …
[HTML][HTML] LINC00926 promotes progression of renal cell carcinoma via regulating miR-30a-5p/SOX4 axis and activating IFNγ-JAK2-STAT1 pathway
L Du, B Wang, M Wu, W Chen, W Wang, W Diao… - Cancer Letters, 2023 - Elsevier
The role of long non-coding RNA (lncRNA) in the progression of renal cell carcinoma (RCC)
remains further study. Whether lncRNA may be used to predict the immunotherapy efficacy …
remains further study. Whether lncRNA may be used to predict the immunotherapy efficacy …
[HTML][HTML] Health-related Quality of Life Assessment in Renal Cell Cancer: A Scoping Review
F Gross, IML Rasmussen, EG Beisland… - European Urology …, 2024 - Elsevier
Background and objective In oncology, patient-reported outcome measures (PROMs)
capturing health-related quality of life (HRQOL) play an increasing role in clinical trials, drug …
capturing health-related quality of life (HRQOL) play an increasing role in clinical trials, drug …
A prognostic signature based on genes associated with m6A/m5C/m1A/m7G modifications and its immunological characteristics in clear cell renal cell carcinoma
W He, Z Cong, C Niu, F Cheng, T Yi, Z Yao, Y Zhang… - Scientific Reports, 2024 - nature.com
Clear cell renal cell carcinoma (ccRCC) is characterized by a high incidence and mortality
rate. Despite advancements in therapeutic interventions, the prognosis for renal cancer …
rate. Despite advancements in therapeutic interventions, the prognosis for renal cancer …
DESCRIPTION OF BASELINE QUALITY OF LIFE IN PATIENTS DIAGNOSED WITH METASTATIC RENAL CELL CARCINOMA
G Lendínez-Cano, CB Congregado Ruíz… - Urologia …, 2024 - karger.com
INTRODUCTION: Renal cancer (RC) is not typically symtomatic until it reaches a
considerable size and an advanced stage (1). The 5-year survival rate for metastatic renal …
considerable size and an advanced stage (1). The 5-year survival rate for metastatic renal …
[PDF][PDF] 基于患者报告结局的肿瘤营养治疗系统临床应用专家共识
中国医师协会肿瘤医师分会… - 肿瘤代谢与营养电子 … - 182.92.200.144
临床结局指标是评估治疗效果和医疗服务质量的关键指标. 传统的临床结局指标忽视了患者的
主观感受, 因此近年来患者报告结局(PRO) 备受关注. 在肿瘤领域, PRO 可用于评估和监测症状 …
主观感受, 因此近年来患者报告结局(PRO) 备受关注. 在肿瘤领域, PRO 可用于评估和监测症状 …
Reply to Yudai Ishiyama and Fumihiko Urabe's Letter to the Editor re: Kosuke Takemura, Audreylie Lemelin, Matthew S. Ernst, et al. Outcomes of Patients with Brain …
K Takemura, T Yuasa, TK Choueiri… - European …, 2024 - pubmed.ncbi.nlm.nih.gov
Reply to Yudai Ishiyama and Fumihiko Urabe's Letter to the Editor re: Kosuke Takemura,
Audreylie Lemelin, Matthew S. Ernst, et al. Outcomes of Patients with Brain Metastases from …
Audreylie Lemelin, Matthew S. Ernst, et al. Outcomes of Patients with Brain Metastases from …
Re: Robert J. Motzer, Pratik P. Rane, Todd L. Saretsky, et al. Patient-reported Outcome Measurement and Reporting for Patients with Advanced Renal Cell Carcinoma …
Re: Robert J. Motzer, Pratik P. Rane, Todd L. Saretsky, et al. Patient-reported Outcome
Measurement and Reporting for Patients with Advanced Renal Cell Carcinoma: A Systematic …
Measurement and Reporting for Patients with Advanced Renal Cell Carcinoma: A Systematic …